MCK
Mckesson Corp Health Care Wholesale-Drugs, Proprietaries & Druggists' Sundries S&P 500Russell 3000
$994.58Close
$278.5BMarket cap
$723.60 – $1,030.1252-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Near its high 3% below its 52-week high
Cautions
- Trend not confirmed 7 of 8 conditions · 150-day under the 200-day
- Earnings shrinking EPS −18% year on year
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
down 0.6%
price change
1mo
up 16.5%
price change
12-month return
up 21%
market up 11% ·
its own up 13%
F-score
5 / 9
Mixed
Altman Z″
0.58
Elevated risk
P/E
58.5×
price / earnings
PEG
1.19
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 2.2%
EBIT / enterprise value
Cheaper than
37%
of the market · expensive
Revenue growth
up 12%
year on year
EPS growth
down 18%
latest quarter · -54 pts
Sales growth
up 8%
latest quarter · +2 pts
ROE
—
return on equity
Free cash margin
up 1%
$5.7B FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
0.4×
Interest cover
—EBIT / interest
Piotroski tests
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- assets working harder
Trade setup
ATR%
2.3%
$23.14 a day · 2×ATR $948.31
RS
78 / 99
vs the universe
Trend
7 / 8
150-day under the 200-day
Relative volume
0.9×
vs 50-day average
Up/down volume
1.07
50 sessions
Implied move
8.2%
by Nov 20, 2026 · report Nov 4, 2026
Trend template · 7 of 8
- 150-day average above the 200-day: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$2.2B as of Mar 31, 2026. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+5% vs market2 sessions after results
Options
$7.6M37.8% IV · activity
Financials
- Gross 4%
- Net 1%
- Free cash 1%
- Cash
- Long-term debt
| FY2021Mar 31, 2021 | FY2022Mar 31, 2022 | FY2023Mar 31, 2023 | FY2024Mar 31, 2024 | FY2025Mar 31, 2025 | FY2026Mar 31, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $238.2B | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Gross margin | 5% | 5% | 4% | 4% | 4% | 4% |
| Operating income | -$5.0B | $2.0B | $4.4B | $3.9B | $4.4B | $6.2B |
| Net income | -$4.5B | $1.1B | $3.6B | $3.0B | $3.3B | $4.8B |
| Net margin | -2% | 0% | 1% | 1% | 1% | 1% |
| Earnings per share | -$28.26 | $7.23 | $25.04 | $22.39 | $25.72 | $38.37 |
| Free cash flow | $4.1B | $4.0B | $4.8B | $3.9B | $5.5B | $5.7B |
| Free cash margin | 2% | 2% | 2% | 1% | 2% | 1% |
| Cash | $6.3B | $3.5B | $4.7B | $4.6B | $5.7B | $4.0B |
| Long-term debt | $6.4B | $5.9B | $5.6B | $5.6B | $5.7B | $6.5B |
| Shareholders' equity | -$21.0M | -$2.3B | -$1.9B | -$2.0B | -$2.1B | -$2.2B |
| Shares outstanding | 273m | 275m | 277m | 278m | 279m | 280m |
Next report
Nov 4, 2026 · after the close
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±8.2%
$913 – $1,076 by Nov 20, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±3.5%
last 4: +4.9% · -1.0% · +12.5% · +2.0%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
2.4× the usual move
What options price now
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 37.8% priced · 22.4% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs more
Positioning
- Premium traded
- $7.6M calls $4.4M · puts $3.2M · latest session
- 0.73× +0.47 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +864 · puts +641 past week
For options traders: ATM IV 37.8% (+4.4% 1w) · 1m ÷ 3m IV 1.29 · 25Δ skew 3.4 pts · Net GEX $8.6M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 8, 2026 | Annual ↗ | Mar 31, 2026 | 38d |
| Feb 4, 2026 | Quarterly ↗ | Dec 31, 2025 | 35d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 9, 2025 | Annual ↗ | Mar 31, 2025 | 39d |
| Feb 6, 2025 | Quarterly ↗ | Dec 31, 2024 | 37d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Annual ↗ | Mar 31, 2024 | 38d |
| Feb 8, 2024 | Quarterly ↗ | Dec 31, 2023 | 39d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 6, 2026 | Regulation FD ↗ |
| Aug 28, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 24, 2026 | Shareholder vote ↗ |
| Jul 1, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 12, 2026 | Material agreement · New obligation ↗ |
| May 7, 2026 | Results ↗ |
| Apr 28, 2026 | Material agreement · Agreement ended · New obligation ↗ |
| Apr 6, 2026 | Material agreement · New obligation ↗ |
| Mar 6, 2026 | Regulation FD ↗ |
| Mar 5, 2026 | Director or officer change ↗ |
| Feb 4, 2026 | Results ↗ |